Our findings confirm that, indeed, anti-CGRP MAbs have opened new therapeutic horizons in migraine prevention based on the corresponding RCTs, which all had an overall adequate methodological quality and predefined outcomes. This evidence concerns the gene CALCA and migraine disorder.